Moderna (MRNA) Other Non Operating Income (2018 - 2026)

Moderna (MRNA) has reported Other Non Operating Income for 9 consecutive years, with -$19.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other Non Operating Income fell 337.5% year-over-year to -$19.0 million in Q2 2026; TTM through Jun 2026 was -$49.0 million, a 32.43% decrease from a year earlier, with the FY2025 full-year figure at -$8.0 million, up 90.8% from the prior year.
• Other Non Operating Income was -$19.0 million for Q2 2026 at Moderna, down from -$18.0 million in the prior quarter.
• Over five years, Other Non Operating Income peaked at $14.0 million in Q2 2023 and troughed at -$51.0 million in Q3 2023.
• A 5-year average of -$17.7 million and a median of -$13.0 million in 2022 frame the typical range for Other Non Operating Income.
• The widest YoY moves for Other Non Operating Income: up 207.69% in 2023, down 628.57% in 2023.
• Over 5 years, Other Non Operating Income stood at -$12.0 million in 2022, then sank by 225.0% to -$39.0 million in 2023, then climbed by 25.64% to -$29.0 million in 2024, then surged by 58.62% to -$12.0 million in 2025, then tumbled by 58.33% to -$19.0 million in 2026.
• The last three Other Non Operating Income figures came in at -$19.0 million (Q2 2026), -$18.0 million (Q1 2026), and -$12.0 million (Q4 2025), per Business Quant data.